Literature DB >> 10487088

The clinical management of male infertility.

K Razvi1, S Chew, E L Yong, J Kumar, S C Ng.   

Abstract

Male infertility is a common cause of subfertility for which sperm disorders are the single most common cause. Genetic abnormalities, for example, microdeletions associated with the Y chromosome, defects in the androgen receptor gene and cystic fibrosis have gained recent prominence and it is envisaged that many of the 60% of men for which no cause is found may have a genetic basis for their subfertility. Although an abnormal semen analysis is commonly the first indicator of a male factor problem, further tests are usually required. Empirical treatment with hormones, varicocelectomy and immunological treatment have been proven to be disappointing whilst the treatment of infection and obstruction do not always translate into significantly higher fertility rates. Ejaculatory disorders and impotence can be effectively treated today whilst donor insemination can be offered to men with untreatable infertility. The advent of assisted reproduction and micromanipulation has greatly improved prospects for fertility of men with very poor semen quality. However, the genetic implications of these procedures have to be quickly addressed so that fertility is maximised without risk to the progeny.

Entities:  

Mesh:

Year:  1999        PMID: 10487088

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  2 in total

1.  Synergistic effects of TIMP2-418G/C and MMP9-1562C/T variants on the male infertility risk.

Authors:  Shiva Roshankhah; Kamran Mansouri; Mitra Bakhtiari; Mohammad Reza Salahshoor; Rezvan Asgari
Journal:  Mol Biol Rep       Date:  2018-12-04       Impact factor: 2.316

2.  Association of spermatogenic failure with the b2/b3 partial AZFc deletion.

Authors:  Abdelmajid Eloualid; Houria Rhaissi; Ahmed Reguig; Safaa Bounaceur; Brahim El Houate; Omar Abidi; Majida Charif; Noureddine Louanjli; Elbakkay Chadli; Abdelhamid Barakat; Anu Bashamboo; Ken McElreavey; Hassan Rouba
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.